225 related articles for article (PubMed ID: 15109977)
1. Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain.
Andersen G; Sjøgren P; Hansen SH; Jensen NH; Christrup L
Eur J Pain; 2004 Jun; 8(3):263-71. PubMed ID: 15109977
[TBL] [Abstract][Full Text] [Related]
2. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine.
Andersen G; Jensen NH; Christrup L; Hansen SH; Sjøgren P
Palliat Med; 2002 Mar; 16(2):107-14. PubMed ID: 11969141
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
Quigley C; Joel S; Patel N; Baksh A; Slevin M
Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
[TBL] [Abstract][Full Text] [Related]
4. The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain.
Lasheen W; Walsh D; Mahmoud F; Sarhill N; Rivera N; Davis M; Lagman R; Legrand S
Palliat Med; 2010 Jan; 24(1):9-16. PubMed ID: 19910396
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M
Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069
[TBL] [Abstract][Full Text] [Related]
6. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial.
Narabayashi M; Saijo Y; Takenoshita S; Chida M; Shimoyama N; Miura T; Tani K; Nishimura K; Onozawa Y; Hosokawa T; Kamoto T; Tsushima T;
Jpn J Clin Oncol; 2008 Apr; 38(4):296-304. PubMed ID: 18326541
[TBL] [Abstract][Full Text] [Related]
7. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
8. A pharmacodynamic study of morphine and its glucuronide metabolites after single morphine dosing in cancer patients with pain.
Hoffman M; Xu JC; Smith C; Fanelli C; Pascal V; Degaetano C; Meenan G; Lehrer M; Lesser M; Citron M
Cancer Invest; 1997; 15(6):542-7. PubMed ID: 9412659
[TBL] [Abstract][Full Text] [Related]
9. The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment.
Takahashi M; Ohara T; Yamanaka H; Shimada A; Nakaho T; Makoto Y
Palliat Med; 2003 Dec; 17(8):673-8. PubMed ID: 14694918
[TBL] [Abstract][Full Text] [Related]
10. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.
Klepstad P; Rakvåg TT; Kaasa S; Holthe M; Dale O; Borchgrevink PC; Baar C; Vikan T; Krokan HE; Skorpen F
Acta Anaesthesiol Scand; 2004 Nov; 48(10):1232-9. PubMed ID: 15504181
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.
Ridgway D; Sopata M; Burneckis A; Jespersen L; Andersen C
J Pain Symptom Manage; 2010 Apr; 39(4):712-20. PubMed ID: 20413058
[TBL] [Abstract][Full Text] [Related]
12. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain.
Glare P; Walsh D; Sheehan D
Am J Hosp Palliat Care; 2006; 23(3):229-35. PubMed ID: 17060284
[TBL] [Abstract][Full Text] [Related]
13. Relationship between plasma concentrations of morphine and its metabolites and pain in cancer patients.
Sakurada T; Takada S; Eguchi H; Izumi K; Satoh N; Ueda S
Pharm World Sci; 2010 Dec; 32(6):737-43. PubMed ID: 20730493
[TBL] [Abstract][Full Text] [Related]
14. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
Wolff T; Samuelsson H; Hedner T
Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
[TBL] [Abstract][Full Text] [Related]
16. Lack of analgesic activity of morphine-6-glucuronide after short-term intravenous administration in healthy volunteers.
Lötsch J; Kobal G; Stockmann A; Brune K; Geisslinger G
Anesthesiology; 1997 Dec; 87(6):1348-58. PubMed ID: 9416720
[TBL] [Abstract][Full Text] [Related]
17. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers.
Heinrich-Nols J; Schug BS; Evers G; Larsimont V; Elze M; Blume HH; Lee LS; Crawford F
Int J Clin Pharmacol Ther; 1999 Mar; 37(3):153-8. PubMed ID: 10190764
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers.
Lötsch J; Stockmann A; Kobal G; Brune K; Waibel R; Schmidt N; Geisslinger G
Clin Pharmacol Ther; 1996 Sep; 60(3):316-25. PubMed ID: 8841154
[TBL] [Abstract][Full Text] [Related]
20. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients.
Tiseo PJ; Thaler HT; Lapin J; Inturrisi CE; Portenoy RK; Foley KM
Pain; 1995 Apr; 61(1):47-54. PubMed ID: 7644248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
